Adam Matthew Forman - Hematology ...

Dr. Adam M. Forman

Claim this profile

Ascension Providence Hospitals - Southfield

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
25 reported clinical trials
46 drugs studied

About Adam M. Forman

Education:

  • Graduated with a Doctor of Medicine (MD) from Wayne State University School of Medicine.
  • Completed Residency in Internal Medicine at St. John Hospital and Medical Center.
  • Undertook a Fellowship in Gastroenterology at Henry Ford Hospital.

Experience:

  • Currently practices as a gastroenterologist at Ascension Providence Hospitals - Southfield.

Area of expertise

1Lung Cancer
Adam M. Forman has run 10 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Adam M. Forman has run 8 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.
Ascension Providence Hospitals - Southfield
Image of trial facility.
Ascension Providence Hospitals - Novi

Clinical Trials Adam M. Forman is currently running

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

More about Adam M. Forman

Clinical Trial Related2 years of experience running clinical trials · Led 25 trials as a Principal Investigator · 13 Active Clinical Trials
Treatments Adam M. Forman has experience with
  • Atezolizumab
  • Carboplatin
  • Pembrolizumab
  • Nivolumab
  • Lenalidomide
  • Durvalumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Adam M. Forman specialize in?
Is Adam M. Forman currently recruiting for clinical trials?
Are there any treatments that Adam M. Forman has studied deeply?
What is the best way to schedule an appointment with Adam M. Forman?
What is the office address of Adam M. Forman?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security